MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
You may also be interested in...
The head of UK agency wants Britain to get its own version of the FDA’s Centers of Excellence in Regulatory Science and Innovation network to promote collaborations between it and academia to advance regulatory science through research, education, and scientific exchanges.
The chairman of Britain’s regulator the MHRA says clinical trials need more adaptive designs using smaller patient numbers if drug development costs are to be cut and innovative therapies made more accessible more quickly.
Biotechs and smaller companies have called for more flexibility and informal dialogue when seeking scientific advice from Europe’s regulators and HTA bodies on the development of their investigational medicines, says a joint survey by EuropaBio and the Deerfield Institute.